BRAF and metastatic melanoma: To test this hypothesis, we longitudinally evaluated Gal‐1 plasma concentrations at subsequent time points during the course of BRAF/MEK inhibitor therapy (first measurement before drug administration) in 9 metastatic melanoma patients (Table S3).